PDK4-IN-1 hydrochloride NEW
| Price | $129 | $316 | $482 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-22 |
Product Details
| Product Name: PDK4-IN-1 hydrochloride | CAS No.: 2310262-11-2 |
| Purity: 99.54% | Supply Ability: 10g |
| Release date: 2025/05/22 |
Product Introduction
Bioactivity
| Name | PDK4-IN-1 hydrochloride |
| Description | PDK4-IN-1 hydrochloride, an anthraquinone derivative, is a potent and orally active inhibitor of pyruvate dehydrogenase kinase 4 (PDK4) with an IC50 value of 84 nM. |
| In vitro | PDK4-IN-1 hydrochloride treatment significantly impedes the proliferation of human colon cancer cell lines, HCT116 and RKO. The colony formation efficiency in HCT116 and RKO cells Is significantly reduced after treatment of PDK4-IN-1[1]. PDK4-IN-1 (Compound 8c; 10-50 μM; 24 hours; HCT116 and RKO cells) treatment dose-dependently increased apoptosis. PDK4-IN-1 decreases the expression of BCL-xL and increases the expression of BAX. Cleavage of PARP1 and caspase 3 are increased by PDK4-IN-1[1]. |
| In vivo | PDK4-IN-1 (C57BL/6J mice) treatment significantly improves glucose tolerance[1]. Pre-incubation with PDK4-IN-1 (compound 8c) dose-dependently inhibits the release of β-hexosaminidase from IgE/antigen-activated BMMCs, |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 125 mg/mL (317.36 mM), Sonication is recommended. |
| Keywords | Pyruvate dehydrogenase kinase | PDK4-IN-1 Hydrochloride | PDK-4-IN-1 hydrochloride | PDK4IN1 hydrochloride | PDK4 IN 1 hydrochloride | PDK4 | PDHK | PDHE1α | PDH kinase | PARP1 | p-Akt | p53 | metabolites | Inhibitor | inhibit | caspase-3 | BCL-xL | BAX | Apoptosis | antidiabetic | anticancer | anti-allergic |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Dextran sulfate sodium salt (MW 4500-5500) | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Anti-Colorectal Cancer Compound Library | Bioactive Compound Library | Antidepressant Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Hematonosis Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-27 | |
| $0.00/10mg |
Hubei Chuchang Biotech Co., Ltd.
|
2024-10-29 | ||
| $98.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $129.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-05-22 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY